162 related articles for article (PubMed ID: 10640588)
1. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing water-soluble prodrugs of paclitaxel.
Ceruti M; Crosasso P; Brusa P; Arpicco S; Dosio F; Cattel L
J Control Release; 2000 Jan; 63(1-2):141-53. PubMed ID: 10640588
[TBL] [Abstract][Full Text] [Related]
2. Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes.
Crosasso P; Ceruti M; Brusa P; Arpicco S; Dosio F; Cattel L
J Control Release; 2000 Jan; 63(1-2):19-30. PubMed ID: 10640577
[TBL] [Abstract][Full Text] [Related]
3. In vivo pharmacokinetic and tissue distribution studies in mice of alternative formulations for local and systemic delivery of Paclitaxel: gel, film, prodrug, liposomes and micelles.
Dhanikula AB; Singh DR; Panchagnula R
Curr Drug Deliv; 2005 Jan; 2(1):35-44. PubMed ID: 16305406
[TBL] [Abstract][Full Text] [Related]
4. Preparation and evaluation of paclitaxel-containing liposomes.
Holvoet C; Vander Heyden Y; Lories G; Plaizier-Vercammen J
Pharmazie; 2007 Feb; 62(2):126-32. PubMed ID: 17341033
[TBL] [Abstract][Full Text] [Related]
5. Preparation and characterization of polymeric pH-sensitive STEALTH® nanoparticles for tumor delivery of a lipophilic prodrug of paclitaxel.
Lundberg BB
Int J Pharm; 2011 Apr; 408(1-2):208-12. PubMed ID: 21296135
[TBL] [Abstract][Full Text] [Related]
6. Novel Taxol formulations: Taxol-containing liposomes.
Straubinger RM; Sharma A; Murray M; Mayhew E
J Natl Cancer Inst Monogr; 1993; (15):69-78. PubMed ID: 7912532
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of water-soluble poly(vinyl alcohol)-paclitaxel conjugate as a macromolecular prodrug.
Kakinoki A; Kaneo Y; Tanaka T; Hosokawa Y
Biol Pharm Bull; 2008 May; 31(5):963-9. PubMed ID: 18451527
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of liposomal paclitaxel against MCF-7 breast cancer cells.
Heney M; Alipour M; Vergidis D; Omri A; Mugabe C; Th'ng J; Suntres Z
Can J Physiol Pharmacol; 2010 Dec; 88(12):1172-80. PubMed ID: 21164564
[TBL] [Abstract][Full Text] [Related]
9. Novel taxol formulations: preparation and characterization of taxol-containing liposomes.
Sharma A; Straubinger RM
Pharm Res; 1994 Jun; 11(6):889-96. PubMed ID: 7937531
[TBL] [Abstract][Full Text] [Related]
10. Preparation and characterization of water-soluble prodrug, liposomes and micelles of Paclitaxel.
Dhanikula AB; Panchagnula R
Curr Drug Deliv; 2005 Jan; 2(1):75-91. PubMed ID: 16305410
[TBL] [Abstract][Full Text] [Related]
11. Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation.
Yang T; Cui FD; Choi MK; Cho JW; Chung SJ; Shim CK; Kim DD
Int J Pharm; 2007 Jun; 338(1-2):317-26. PubMed ID: 17368984
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, Biological Evaluation and Low-Toxic Formulation Development of Glycosylated Paclitaxel Prodrugs.
Mao Y; Zhang Y; Luo Z; Zhan R; Xu H; Chen W; Huang H
Molecules; 2018 Dec; 23(12):. PubMed ID: 30563132
[TBL] [Abstract][Full Text] [Related]
13. Lyophilized paclitaxel magnetoliposomes as a potential drug delivery system for breast carcinoma via parenteral administration: in vitro and in vivo studies.
Zhang JQ; Zhang ZR; Yang H; Tan QY; Qin SR; Qiu XL
Pharm Res; 2005 Apr; 22(4):573-83. PubMed ID: 15846465
[TBL] [Abstract][Full Text] [Related]
14. Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel.
Meerum Terwogt JM; ten Bokkel Huinink WW; Schellens JH; Schot M; Mandjes IA; Zurlo MG; Rocchetti M; Rosing H; Koopman FJ; Beijnen JH
Anticancer Drugs; 2001 Apr; 12(4):315-23. PubMed ID: 11335787
[TBL] [Abstract][Full Text] [Related]
15. Liposome formulation of paclitaxel with enhanced solubility and stability.
Yang T; Cui FD; Choi MK; Lin H; Chung SJ; Shim CK; Kim DD
Drug Deliv; 2007 Jul; 14(5):301-8. PubMed ID: 17613018
[TBL] [Abstract][Full Text] [Related]
16. Preparation, Characterization, and Pharmacokinetic Study of a Novel Long-Acting Targeted Paclitaxel Liposome with Antitumor Activity.
Han B; Yang Y; Chen J; Tang H; Sun Y; Zhang Z; Wang Z; Li Y; Li Y; Luan X; Li Q; Ren Z; Zhou X; Cong D; Liu Z; Meng Q; Sun F; Pei J
Int J Nanomedicine; 2020; 15():553-571. PubMed ID: 32158208
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and selective cytotoxicity of a hyaluronic acid-antitumor bioconjugate.
Luo Y; Prestwich GD
Bioconjug Chem; 1999; 10(5):755-63. PubMed ID: 10502340
[TBL] [Abstract][Full Text] [Related]
18. Novel therapeutic nano-particles (lipocores): trapping poorly water soluble compounds.
Perkins WR; Ahmad I; Li X; Hirsh DJ; Masters GR; Fecko CJ; Lee J; Ali S; Nguyen J; Schupsky J; Herbert C; Janoff AS; Mayhew E
Int J Pharm; 2000 Apr; 200(1):27-39. PubMed ID: 10845683
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of paclitaxel-containing liposomes in rats.
Fetterly GJ; Straubinger RM
AAPS PharmSci; 2003 Nov; 5(4):E32. PubMed ID: 15198520
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin receptor-mediated specific delivery of paclitaxel prodrugs for efficient cancer therapy.
Huo M; Zhu Q; Wu Q; Yin T; Wang L; Yin L; Zhou J
J Pharm Sci; 2015 Jun; 104(6):2018-2028. PubMed ID: 25820241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
